GlycoVaxyn | Date: 2014-09-23
GlycoVaxyn | Date: 2013-10-11
Described herein are novel methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
GlycoVaxyn | Date: 2012-09-06
Provided herein are prokaryotic cells capable of producing bioconjugates comprising glycosylated proteins. Also provided herein are compositions comprising such bioconjugates and/or comprising the saccharide moieties of such bioconjugates, as well as methods of vaccinating subjects using such compositions.
GlycoVaxyn | Date: 2010-11-16
The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.
GlycoVaxyn | Date: 2014-10-23
The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.